"Naphazoline"

Naphazoline intoxication managed with minimally invasive cardiac output monitoring. Naphazoline, a nonspecific alpha-adrenoceptor stimulant, is a potent vasoconstrictor used in nasal sprays, eye drops, and over-the-counter antiseptics. Naphazoline intoxication increases afterload by constricting the peripheral arteries, which can lead to complications including multiple organ failure. Although phentolamine, a nonselective alpha-adrenoceptor antagonist, and nicardipine, a calcium channel blocker, are used for the treatment of naphazoline intoxication, no established administration protocols currently exist. We present the case of a 32-year-old male with depression who ingested 150 mL of an antiseptic containing 0.1% naphazoline (equivalent to 150 mg of naphazoline). Five hours after ingestion

Evaluation of Gingival Displacement with Aluminum Chloride and Naphazoline Hydrochloride: A Randomized Controlled Trial. The objective of this study was to evaluate the use of naphazoline hydrochloride in comparison with aluminum chloride for vertical gingival displacement. The inclusion criteria were: patients with a good general systemic condition; periodontal health; and thick gingival biotype gingival displacement was calculated. A descriptive analysis of the average displacement was performed. The normality test used was the Lilliefors' Test and for comparison between treatments, the Kruskal-Wallis Test was used. The Bartlett's Test for homogeneity of variances was used and a 5% (p ⟨ 0.05) significant level was considered. Thus, the Aluminum Chloride and Naphazoline Hydrochloride showed

Exposure to antazoline-naphazoline eye drops during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study. To investigate whether exposure to antazoline-naphazoline eye drops in the first trimester of pregnancy was associated with an increased risk of malformations in humans. All women giving live birth between 1997 and 2011 in Denmark were included in this nationwide cohort study. All women redeeming at least one prescription of antazoline-naphazoline eye drops during the first 84 days of pregnancy were identified. Logistic regression was used to estimate the odds ratios of malformations among exposed offspring compared to non-exposed offspring. We identified 977 706 births between 1997 and 2011. A total of 3061 women (0.32%) were exposed to antazoline

Tissue Hypoperfusion, Hypercoagulopathy, and Kidney and Liver Dysfunction after Ingestion of a Naphazoline-Containing Antiseptic Naphazoline is a peripheral -adrenergic receptor agonist commonly used as a topical decongestant. In Japan, over-the-counter antiseptics often contain naphazoline to effect local hemostasis. We present the first case involving the development of hypercoagulopathy , with kidney and liver dysfunction, following a naphazoline overdose. A 22-year-old Japanese woman with a history of depression ingested 160 mL of a commercially available antiseptic containing 0.1% naphazoline. Three days later, she was brought to the emergency department because of general fatigue, nausea, and vomiting. Physical examination revealed cool, pale extremities. Laboratory data showed evidence

Impact of local anesthesia on ciliary dyskinesia diagnosis by digital high-speed videomicroscopy. This prospective study investigates the impact of local anesthesia on ciliary function in nasal epithelium. The primary objective was to assess whether lidocaine 2% and naphazoline 0.5% nasal spray alter ciliary beat frequency and pattern in subjects undergoing nasal brushing, aiming to enhance of 25 healthy volunteers and 13 referred individuals (including seven diagnosed with PCD). Selection criteria ensured the absence of chronic respiratory diseases, recent respiratory tract infections, or regular use of nasal medications. Participants underwent nasal brushing with administration of lidocaine and naphazoline nasal spray in one nostril and saline in the contralateral nostril. Ciliary beat

studies were rated level III. Medications that provided short-term improvement in blepharoptosis included phenylephrine, cocaine, hydroxyamphetamine, apraclonidine, naphazoline, and oxymetazoline. Phenylephrine, cocaine, and hydroxyamphetamine were used only in the office for diagnostic purposes. No serious, treatment-related adverse events were noted in the studies included in this assessment. Adverse events reported included dry mouth and dry nose with apraclonidine and punctate keratitis and blurred vision, conjunctival hyperemia, dry eye, and instillation site pain with oxymetazoline. Phenylephrine, cocaine, hydroxyamphetamine, apraclonidine, naphazoline, and oxymetazoline can achieve short-term blepharoptosis correction. Phenylephrine, cocaine, and hydroxyamphetamine have been described only

antidepressantsVenlafaxine (Effexor)DepressionRisk of cardiac disordersOther antidepressantsBupropion (Zyban)Smoking cessationRisk of neuropsychiatric disordersNicotineOral or Nasal Decongestants: Pseudo-ephedrine, Naphazoline, PhenylephrineAllergic or viral rhinitisSerious cardiovascular disordersConservative measuresOmalizumab (Xolair), Mepolizumab (Nucala)Severe asthma, chronic idiopathic urticariaDisproportionate

was to clinically evaluate the efficacy of naphazoline as a gingival retraction agent. The secondary aim was to compare it with tetrahydrozoline and aluminum chloride. Fifteen patients participated in a randomized crossover clinical trial at the Army College of Dental Sciences, Secunderabad, Telangana, India. Preliminary maxillary impressions were made with irreversible hydrocolloid for all patients to fabricate custom trays. After that, baseline impressions and cast for control group measurements were prepared. Gingival displacement was carried out in the right maxillary central incisor for all, with retraction cord soaked in three agents, either, aluminum chloride, tetrahydrozoline, or naphazoline. These agents were used in all patients with a washout period of 14 days. Elastomeric monophase impressions

: 0.13-0.71%) were drug related. Tetracaine eye drops accounted for 4 (80%, 95% CI: 38-96%) cases with corneal involvement. The other case was an intense conjunctival injection due to naphazoline eye drops. ADEs should be considered in differential diagnosis of ocular emergency problems and preventive measure should be considered.

%, or naphazoline 0.05% to the left eye. There was no statistically significant difference in mean MRD1 between the brimonidine and phenylephrine groups when comparing baseline to all other study time points. After administration of naphazoline 0.05%, MRD1 had a mean increase of 0.56 ± 0.11 mm (p < 0.001) after 30 minutes, 0.47 ± 0.12 mm (p = 0.001) after 60 minutes, and 0.26 ± 0.09 mm (p = 0.028) after 120 minutes when compared with baseline. Brimonidine 0.2% and phenylephrine 0.12% have no effect on eyelid aperture, but naphazoline 0.05% eyedrops could be useful for temporary relief of upper eyelid ptosis in selected patients.

octopamine. Naphazoline possessed the highest agonistic activity among the tested agonists. In antagonistic assays, mianserin had the strongest activity and was followed by phentolamine and chlorpromazine. Furthermore, when the flies were kept under starvation, there was a corresponding increase in the transcript level of BdOctβR1, while high or low temperature stress could not induce significant

bepotastine/ (197)29 epinastine/ (680)30 naphazoline plus pheniramine maleate/ or naphazoline/ (1791)31 pheniramine/ (925)32 hydrocortisone/ (161604)33 loteprednol etabonate/ or loteprednol/ or loteprednol etabonate plus tobramycin/ (1143)34 fluorometholone acetate/ or fluorometholone/ or fluorometholone plus neomycin/ or fluorometholone acetate plus tobramycin/ (2546)35 desonide/ (1265)36 rimexolone/ (350 )) OR (cyclosporin)) OR (immunomodulator)) OR (levocabastine)) OR (cromoglycate)) OR (cromoglycate disodium)) OR (ketotifen)) OR (olopatadine)) OR (azelastine)) OR (nedocromil)) OR (emedastine)) OR (alcaftadine)) OR (bepotastine)) OR (epinastine)) OR (naphazoline)) OR (pheniramine)) OR (hydrocortisone)) OR (loteprednol)) OR (fluorometholone)) OR (desonide)) OR (rimexolone)) OR (prednisolone)) OR (dexamethasone

Antihistamines 1. Naphazoline (Vasocon, Naphcon) 1 drop twice to four times daily prn 2. Epinastine (Elestat) 0.05% 1 drop each eye twice daily 3. Bepotastine (Bepreve) 1.5% 1 drop each eye twice daily 4. Alcaftadine (Lastacraft, OTC as of 2022) 0.25% (2.5 mg/mL) one drop in each eye daily 3. Ocular NSAIDs 1. Ketorolac 0.5% (Acular) 1 drop four times daily for 7 days 2. Diclofenac 0.1

* Extra: Related Studies * Extra: Navigation Tree advertisement II. Preparations: NSAIDs 1. Ketorolac (Acular) 1 drop qid III. Preparations: Antihistamine-Decongestant 1. Contraindications 1. Avoid in Narrow Angle Glaucoma 2. Preparations: Naphazoline and Pheniramine maleate 1. Brand Names: Opcon-A, Naphcon-A 2. Dose: 1-2 drops q4h up to qid IV. Preparations: Mast Cell

to Palliative Care * * Administration * Patient Satisfaction * Documentation 4 * * advertisement * Home * Ophthalmology Book * Pharmacology Chapter * Ocular Antihistamine Ocular Antihistamine Aka: Ocular Antihistamine, Naphazoline, Vasocon, Naphcon, Epinastine, Elestat, Bepotastine, Bepreve, Alcaftadine, Lastacraft Ophthalmology Ocular Effects * Contact Lens * See Also * Page Contents * Antihistamine * Allergic Conjunctivitis * Ocular Mast Cell Stabilizer * Page Contents... * Indications * Preparations * Extra: Related Bing Images * Extra: Related Studies * Extra: Medication Costs * Extra: Navigation Tree advertisement II. Indications 1. Allergic Conjunctivitis III. Preparations 1. Naphazoline

and causes vasoconstriction. Rebound vasodilation may be induced through weak affinity toward beta-adrenoreceptors. Imidazolines (eg, oxymetazoline [9] , xylometazoline, naphazoline, clonidine) cause vasoconstriction primarily through alpha2-adrenergic receptors, but may also decrease endogenous norepinephrine though a negative feedback mechanism.Benzalkonium chlorideBenzalkonium chloride (BKC